<DrugInformationSummary id="CDR0000640318"><DrugInfoMetaData><DrugInfoType>Brief</DrugInfoType><DrugInfoAudience>Patients</DrugInfoAudience><DrugInfoDescription>Everolimus works by blocking the activity of a protein called mTOR, a kinase (enzyme) that is found in high amounts in some cancer cells. Blocking mTOR stops the growth of cancer cells and the growth of blood vessels that support tumor growth. Everolimus also lowers the body’s immune response. Everolimus is a targeted therapy drug that acts as a kinase inhibitor, an angiogenesis inhibitor, and an immunosuppressant. </DrugInfoDescription><DrugInfoURL xref="https://www.cancer.gov/about-cancer/treatment/drugs/everolimus">Everolimus</DrugInfoURL><FDAApproved>Yes</FDAApproved><TerminologyLink ref="CDR0000372905">everolimus</TerminologyLink><GlossaryLink ref="CDR0000386203">everolimus</GlossaryLink><USBrandNames><USBrandName>Afinitor</USBrandName><USBrandName>Zortress</USBrandName></USBrandNames><PronunciationInfo><TermPronunciation>eh-veh-ROH-lih-mus</TermPronunciation><MediaLink ref="CDR0000713182" type="audio/mpeg" alt="" language="en" id="_3"/><MediaLink ref="CDR0000713181" type="audio/mpeg" alt="" language="es" id="_4"/></PronunciationInfo><FDAExternalRef xref="https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&amp;query=EVEROLIMUS&amp;pagesize=20&amp;page=1&amp;audience=consumer">FDA label information for this drug is available at DailyMed.</FDAExternalRef></DrugInfoMetaData><DrugInfoTitle>Everolimus</DrugInfoTitle><Section id="_FDA"><Para><ExternalRef xref="https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&amp;query=EVEROLIMUS&amp;pagesize=20&amp;page=1&amp;audience=consumer">FDA label information for this drug is available at DailyMed.</ExternalRef></Para></Section><Section id="_1"><Title>Use in Cancer</Title>                                                              
  <Para id="_2">Everolimus is approved to treat:</Para>                          
 <ItemizedList Style="bullet" id="_7"><ListItem><Strong><GlossaryTermRef href="CDR0000444971" dictionary="Cancer.gov" audience="Patient">Breast cancer</GlossaryTermRef>.</Strong> It is used in <GlossaryTermRef href="CDR0000045650" dictionary="Cancer.gov" audience="Patient">combination</GlossaryTermRef> with <GlossaryTermRef href="CDR0000045445" dictionary="Cancer.gov" audience="Patient">exemestane</GlossaryTermRef> in <GlossaryTermRef href="CDR0000045269" dictionary="Cancer.gov" audience="Patient">postmenopausal</GlossaryTermRef> women with <GlossaryTermRef href="CDR0000478743" dictionary="Cancer.gov" audience="Patient">advanced</GlossaryTermRef> <GlossaryTermRef href="CDR0000788029" dictionary="Cancer.gov" audience="Patient">hormone receptor–positive</GlossaryTermRef> (HR+) breast cancer that is also  <GlossaryTermRef href="CDR0000774531" dictionary="Cancer.gov" audience="Patient">HER2 negative</GlossaryTermRef> (HER2-) and has not gotten better after treatment with <GlossaryTermRef href="CDR0000045421" dictionary="Cancer.gov" audience="Patient">letrozole</GlossaryTermRef> or <GlossaryTermRef href="CDR0000045504" dictionary="Cancer.gov" audience="Patient">anastrozole</GlossaryTermRef>.</ListItem><ListItem><Strong><GlossaryTermRef href="CDR0000044904" dictionary="Cancer.gov" audience="Patient">Neuroendocrine tumors</GlossaryTermRef></Strong> that are <GlossaryTermRef href="CDR0000045850" dictionary="Cancer.gov" audience="Patient">progressive</GlossaryTermRef>, <GlossaryTermRef href="CDR0000774690" dictionary="Cancer.gov" audience="Patient">well-differentiated</GlossaryTermRef>, <GlossaryTermRef href="CDR0000458095" dictionary="Cancer.gov" audience="Patient">nonfunctioning</GlossaryTermRef> and of <GlossaryTermRef href="CDR0000045692" dictionary="Cancer.gov" audience="Patient">gastrointestinal</GlossaryTermRef> (GI) or <GlossaryTermRef href="CDR0000270740" dictionary="Cancer.gov" audience="Patient">lung</GlossaryTermRef> origin. It is used for tumors that cannot be removed by surgery, are <GlossaryTermRef href="CDR0000045955" dictionary="Cancer.gov" audience="Patient">locally advanced</GlossaryTermRef>, or have <GlossaryTermRef href="CDR0000046283" dictionary="Cancer.gov" audience="Patient">metastasized</GlossaryTermRef> (spread to other parts of the body).</ListItem><ListItem><Strong><GlossaryTermRef href="CDR0000753531" dictionary="Cancer.gov" audience="Patient">Pancreatic neuroendocrine tumors</GlossaryTermRef></Strong> that are  progressive. It is used for tumors that cannot be removed by surgery, are locally advanced, or have metastasized.</ListItem><ListItem><Strong><GlossaryTermRef href="CDR0000661352" dictionary="Cancer.gov" audience="Patient">Renal cell carcinoma</GlossaryTermRef></Strong> (a type of <GlossaryTermRef href="CDR0000444995" dictionary="Cancer.gov" audience="Patient">kidney cancer</GlossaryTermRef>) that is advanced, in adults who have not gotten better after treatment with <GlossaryTermRef href="CDR0000468779" dictionary="Cancer.gov" audience="Patient">sunitinib</GlossaryTermRef> or <GlossaryTermRef href="CDR0000509041" dictionary="Cancer.gov" audience="Patient">sorafenib</GlossaryTermRef>.</ListItem><ListItem><Strong><GlossaryTermRef href="CDR0000689357" dictionary="Cancer.gov" audience="Patient">Subependymal giant cell astrocytoma</GlossaryTermRef></Strong> in adults and children aged 1 year or older who have <GlossaryTermRef href="CDR0000304692" dictionary="Cancer.gov" audience="Patient">tuberous sclerosis</GlossaryTermRef> and are not able to have surgery.</ListItem></ItemizedList><Para id="_8">The use of everolimus to treat cancer is approved for the Afinitor and Afinitor Disperz brands. Everolimus is also approved to treat <GlossaryTermRef href="CDR0000046631" dictionary="Cancer.gov" audience="Patient">transplant</GlossaryTermRef> rejection. This use is approved for the Zortress brand.</Para><Para id="_4">Everolimus is also being studied in the treatment of other types of cancer. </Para></Section><Section id="_About"><Title>More About Everolimus</Title><Para id="_Dict_1"><ExternalRef xref="https://www.cancer.gov/publications/dictionaries/cancer-drug/def/372905">Definition from the NCI Drug Dictionary</ExternalRef> - Detailed scientific definition and other names for this drug.</Para>

<Para id="_About_8.16">MedlinePlus Information on <ExternalRef xref="https://medlineplus.gov/druginfo/meds/a609032.html">Everolimus</ExternalRef> - A lay language summary of important information about this drug that may include the following:</Para>
<ItemizedList Style="bullet" id="_About_9.17"><ListItem>warnings about this drug,</ListItem><ListItem>what this drug is used for and how it is used,</ListItem><ListItem>what you should tell your doctor before using this drug,</ListItem><ListItem>what you should know about this drug before using it, </ListItem><ListItem>other drugs that may interact with this drug, and</ListItem><ListItem>possible side effects.  </ListItem></ItemizedList><Para id="_About_10.18">Drugs are often studied to find out if they can help treat or prevent conditions other than the ones they are approved for.  This patient information sheet applies only to approved uses of the drug.  However, much of the information may also apply to unapproved uses that are being studied.</Para></Section><Section id="_Research"><Title>Research Results and Related Resources</Title><Para><ExternalRef xref="https://www.cancer.gov/about-cancer/treatment/types/targeted-therapies">Targeted Therapy to Treat Cancer</ExternalRef></Para></Section><Section id="_ClinicalTrial_1"><Title>Clinical Trials Accepting Patients</Title><Para id="_ClinicalTrial_2"><ExternalRef xref="https://www.cancer.gov/research/participate/clinical-trials/intervention/C48387">Find Clinical Trials for Everolimus</ExternalRef> - Check for trials from NCI's list of cancer clinical trials now accepting patients.</Para></Section> 
  <DrugInfoDisclaimer>


<Para id="_Disclaimer_4"><Strong>Important: </Strong>The drug information on this page is meant to be educational. It is not a substitute for medical advice. The information may not cover all possible uses, actions, interactions, or side effects of this drug, or precautions to be taken while using it. Please see your health care professional for more information about your specific medical condition and the use of this drug.
</Para></DrugInfoDisclaimer> 
  <DateFirstPublished>2009-04-21</DateFirstPublished><DateLastModified>2025-02-13</DateLastModified></DrugInformationSummary>
